“`html
Johnson & Johnson (JNJ) has an average brokerage recommendation (ABR) of 2.00, classified as a “Buy,” based on evaluations from 26 brokerage firms. Among these, 12 ratings are “Strong Buy,” and 2 ratings are “Buy,” contributing to 46.2% and 7.7% of total recommendations, respectively.
While the ABR suggests a favorable outlook for JNJ, concerns exist about the reliability of brokerage recommendations due to potential biases stemming from firms’ interests. The Zacks Rank for JNJ currently stands at #3 (Hold), reflecting stable earnings estimates of $10.86 for the current year, indicating a cautious perspective despite the positive ABR.
“`
